Samsung Biologics Co selects SailPoint Identity Platform for Identity and Access Management (IAM)
In 2022, Samsung Biologics Co, a South Korea based Life Sciences organization with 4400 employees and revenues of $1.2B selected SailPoint Identity Platform for Identity and Access Management (IAM) while displacing Legacy, and integrating with the existing systems being used.
| Customer | Vendor | Old Product | New Product | Category | Market | Users | VAR/SI | When | Live | Samsung Biologics Co | SailPoint Technologies | Legacy | SailPoint Identity Platform | Identity and Access Management (IAM) | CyberSecurity | n/a | n/a | 2022 | 2022 |
|---|
Discover the latest software purchases and digital transformation initiatives being undertaken by Samsung Biologics Co and its business and technology executives by accessing the entire Samsung Biologics Co and its business and technology executives by becoming a Premium Subscriber. On a continuous basis, our research team identifies and updates the on-prem and cloud applications that are being used by Samsung Biologics Co employees from publicly available data (Press Releases, Customer References, Case Studies, Success Stories, Testimonials, RFP, RFI, etc.) as well as proprietary sources, and incorporate them into the customer profile.
Don't miss the entire: Samsung Biologics Co Technographics profile